Vowst™
Drug - Vowst™ (fecal microbiota spores, live-brpk) [Seres Therapeutics, Inc.]
January 2025
Therapeutic area - Antibiotics, GI
Approval criteria:
- Patient ≥ 18 years of age; AND
- Patient has a confirmed diagnosis of recurrent Clostridioides difficile infection (CDI) with a total of ≥3 episodes of CDI within 12 months; AND
- Antibiotic treatment for recurrent CDI must be completed 2 to 4 days prior to initiation of Vowst therapy; AND
- Vowst must not be taken concurrently with antibacterials; AND
- Patient will take 10 oz of magnesium citrate (or 250 mL polyethylene glycol electrolyte solution for patients with impaired kidney function) the evening prior to initiation of Vowst therapy; AND
- Patient must not have absolute neutrophil count (ANC) < 500 cells/mm3, toxic megacolon, or small bowel ileus AND
- Vowst is prescribed by, or in consultation with an infectious disease or gastrointestinal specialist
Quantity limits
- 12 capsules per 3-day course
Background
Vowst is not indicated for treatment of CDI.
Questions?
Provider Call Center (844) 575-7887
